Literature DB >> 15547003

Interplay of diabetes and coronary heart disease on cardiovascular mortality.

F Boccara, A Cohen.   

Abstract

Patients with both diabetes mellitus and prior myocardial infarction are at particularly high risk for cardiovascular mortality.

Entities:  

Mesh：

Year:  2004        PMID： 15547003      PMCID： PMC1768583          DOI： 10.1136/hrt.2004.035766

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


  16 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

2.  The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up.

Authors:  F B Hu; M J Stampfer; C G Solomon; S Liu; W C Willett; F E Speizer; D M Nathan; J E Manson
Journal:  Arch Intern Med       Date:  2001-07-23

3.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

4.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven Snapinn
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

5.  Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies.

Authors:  Josie M M Evans; Jixian Wang; Andrew D Morris
Journal:  BMJ       Date:  2002-04-20

6.  Diabetes and all-cause and coronary heart disease mortality among US male physicians.

Authors:  P A Lotufo; J M Gaziano; C U Chae; U A Ajani; G Moreno-John; J E Buring; J E Manson
Journal:  Arch Intern Med       Date:  2001-01-22

7.  The impact of diabetes mellitus and prior myocardial infarction on mortality from all causes and from coronary heart disease in men.

Authors:  Eunyoung Cho; Eric B Rimm; Meir J Stampfer; Walter C Willett; Frank B Hu
Journal:  J Am Coll Cardiol       Date:  2002-09-04       Impact factor: 24.094

8.  Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction.

Authors:  Chong Do Lee; Aaron R Folsom; James S Pankow; Frederick L Brancati
Journal:  Circulation       Date:  2004-02-02       Impact factor: 29.690

9.  Diabetes and cardiovascular disease. The Framingham study.

Authors:  W B Kannel; D L McGee
Journal:  JAMA       Date:  1979-05-11       Impact factor: 56.272

10.  Cardiovascular events in type 2 diabetes: comparison with nondiabetic individuals without and with prior cardiovascular disease. 10-year follow-up of the Hoorn Study.

Authors:  Annemarie Becker; Griët Bos; Femmie de Vegt; Piet J Kostense; Jacqueline M Dekker; Giel Nijpels; Robert J Heine; Lex M Bouter; Coen D A Stehouwer
Journal:  Eur Heart J       Date:  2003-08       Impact factor: 29.983
View more
  9 in total

Review 1.  Intracardiac intracellular angiotensin system in diabetes.

Authors:  Rajesh Kumar; Qian Chen Yong; Candice M Thomas; Kenneth M Baker
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-12-14       Impact factor: 3.619

2.  A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.

Authors:  Dominic P Tilden; Segundo Mariz; Gillies O'Bryan-Tear; Julia Bottomley; Alexander Diamantopoulos
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

Review 3.  The intracellular renin-angiotensin system in the heart.

Authors:  Rajesh Kumar; Vivek P Singh; Kenneth M Baker
Journal:  Curr Hypertens Rep       Date:  2009-04       Impact factor: 5.369

4.  Comparative vascular responses three months after paclitaxel and everolimus-eluting stent implantation in streptozotocin-induced diabetic porcine coronary arteries.

Authors:  Alexander Sheehy; Steven Hsu; Amelie Bouchard; Pablo Lema; Claudine Savard; Louis-Georges Guy; Julie Tai; Igor Polyakov
Journal:  Cardiovasc Diabetol       Date:  2012-06-21       Impact factor: 9.951

5.  Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).

Authors:  Marwa A Sabe; Brian Claggett; Emmanuel A Burdmann; Akshay S Desai; Peter Ivanovich; Reshma Kewalramani; Eldrin F Lewis; John J V McMurray; Kurt A Olson; Patrick Parfrey; Scott D Solomon; Marc A Pfeffer
Journal:  J Am Heart Assoc       Date:  2016-04-23       Impact factor: 5.501

6.  Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus.

Authors:  Marc Evans; Plamen Kozlovski; Päivi M Paldánius; James E Foley; Vaishali Bhosekar; Carmen Serban; Angelo Avogaro
Journal:  Diabetes Ther       Date:  2017-11-13       Impact factor: 2.945

7.  Cardiovascular outcomes of vildagliptin in patients with type 2 diabetes mellitus after acute coronary syndrome or acute ischemic stroke.

Authors:  Dong-Yi Chen; Yan-Rong Li; Chun-Tai Mao; Chi-Nan Tseng; I-Chang Hsieh; Ming-Jui Hung; Pao-Hsien Chu; Chao-Hung Wang; Ming-Shien Wen; Wen-Jin Cherng; Tien-Hsing Chen
Journal:  J Diabetes Investig       Date:  2019-06-17       Impact factor: 4.232

8.  Similar major cardiovascular outcomes between pure statin and ezetimibe-statin in comparable intensity for type 2 diabetes with extremely atherosclerotic risks.

Authors:  Yu-Cheng Kao; Tien-Hsing Chen; Chi-Hung Liu; Jawl-Shan Hwang; Ching-Chung Hsiao; Yu-Sheng Lin; Chun-Tai Mao; Ming-Jui Hung; Yan-Rong Li
Journal:  Sci Rep       Date:  2021-03-23       Impact factor: 4.379

9.  Neointimal hyperplasia persists at six months after sirolimus-eluting stent implantation in diabetic porcine.

Authors:  Qi Zhang; Lin Lu; LiJin Pu; RuiYan Zhang; Jie Shen; ZhengBing Zhu; Jian Hu; ZhenKun Yang; QiuJin Chen; WeiFeng Shen
Journal:  Cardiovasc Diabetol       Date:  2007-06-05       Impact factor: 9.951
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.